These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3367672)

  • 1. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia.
    Jehn U; Göldel N; Rienmüller R; Wilmanns W
    Med Oncol Tumor Pharmacother; 1988; 5(1):41-7. PubMed ID: 3367672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Jehn U; Heinemann V
    Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
    Tham RT; Peters WG; de Bruïne FT; Willemze R
    AJR Am J Roentgenol; 1987 Jul; 149(1):23-7. PubMed ID: 3495987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
    Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
    Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
    Leuk Lymphoma; 1993; 10 Suppl():133-7. PubMed ID: 8481662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.
    Haupt HM; Hutchins GM; Moore GW
    Am J Med; 1981 Feb; 70(2):256-61. PubMed ID: 7468613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma.
    Peters WG; Willemze R; Colly LP
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):401-5. PubMed ID: 3609104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
    Freund M; Link H; Diedrich H; LeBlanc S; Wilke HJ; Poliwoda H
    Cancer Chemother Pharmacol; 1991; 28(6):487-90. PubMed ID: 1934254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
    Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
    Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia.
    Shearer P; Katz J; Bozeman P; Jenkins J; Laver J; Krance R; Hurwitz C; Mahmoud H; Mirro J
    Cancer; 1994 Oct; 74(7):1953-8. PubMed ID: 8082101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
    Jehn U; Heinemann V
    Ann Hematol; 1993 Mar; 66(3):131-4. PubMed ID: 8471658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.